**Investigating the Structure-Activity Relationship of Laulimalides Marine Macrolides as Promising Inhibitors for SARS-CoV-2 Main Protease (Mpro)**

Alaa M. Elgohary1, Abdo A. Elfiky,1\* Florbela Pereira2, Mariam I. Gamal El-Din3,4, Mohamed A. Tammam5, Adnane Aouidate,6 and Amr El-Demerdash7,8,9\*

1Department of Biophysics, Faculty of Science, Cairo University, Giza, 12613, Egypt

2 LAQV‑REQUIMTE, Department of Chemistry, NOVA School of Science and Technology, Universidade Nova de Lisboa, 2829‑516 Caparica, Portugal

3Department of Pharmacognosy, Faculty of Pharmacy, Ain-Shams University, 11566, Cairo, Egypt

4Quadram Institute Bioscience, Norwich Research Park, Norwich, Norfolk NR4 7UQ, UK

5Department of Biochemistry, Faculty of Agriculture, Fayoum University, Fayoum 63514, Egypt

6Laboratory of Organic Chemistry and Physical Chemistry, Team of Molecular Modeling, Materials and Environment, Faculty of Sciences- University ibn Zohr, Agadir, Morocco

7School of Chemistry, Pharmacy and pgarmacology, University of East Anglia, Norwich Research Park, Norwich NR4 7UH, UK

8Department ofBiochemistry and Metabolism, the John Innes Centre, Norwich Research Park, Norwich NR4 7UH, UK

9Division of Organic Chemistry, Department of Chemistry, Faculty of Sciences, Mansoura University, Mansoura, 35516, Egypt

-------------------------------------------------------------------------------------------------------------------------------

\*Correspondences: [A.Eldemerdash@uea.ac.uk](mailto:A.Eldemerdash@uea.ac.uk); [a\_eldemerdash83@mans.edu.eg](mailto:a_eldemerdash83@mans.edu.eg), (Amr El-Demerdash) +44 7834240424 [dr\_abdo@cu.edu.eg](mailto:dr_abdo@cu.edu.eg), (Abdo A. Elfiky). Tel: +201003260523

**Abbreviations:**

**ADME:** Absorption, distribution, metabolism, and excretion

**COVID-19:** Coronavirus disease 2019

**SARS-CoV-2:** severe acute respiratory syndrome-coronavirus 2

**MDMs:** Marine Derived Macrolides

**LMM**: Laulimalides Marine Macrolides

**MNPs**: Marine Natural Products

**MPro**: Main Protease

**MD**: Molecular Dynamics

**SARs**: Structure-Activity Relationships

**VMD**: Visual Molecular Dynamics

**RMSD**: Root Mean Square Deviation

**RMSF**: Root Mean Square Fluctuation

**MM-GBSA**: Molecular Mechanics-Generalized Born Surface Area

**SASA**: Solvent Accessible Surface Area

**Abstract**

SARS-CoV-2, the new coronavirus variant has been a worldwide health crisis that may outbreak any time in the future. Over spans of human history, preparations derived from natural products have always been recognized as a preliminary source of medications. Taking into account the SARS-CoV-2 main protease (Mpro) as the essential element of the viral cycle and as a main target, herein we highlight a computer-aided comprehensive virtual screening for a focused chemical list of 14 laulimalides marine macrolides against SARS-CoV-2 main protease (Mpro) using a set of integrated modern computational techniques including molecular docking (MDock), molecule dynamic simulations (MDS) and structure-activity relationships (SARs). Based on their remarkable ligand-protein energy scores and relevant binding affinities with SARS-CoV-2 (Mpro) pocket residues, two promising macrolides [laulimalides LA4 (**6**) and LA18 (**13**)] are selected as proposed inhibitor compounds. Consequently, they are thermodynamically investigated by deciphering their MD simulations at 100 ns, where they show noticeable stability within the accommodated (Mpro) pockets. Moreover, in-deep SARs studies suggest crucial roles for C-23 substituted side chain and C-20 methoxy as essential pharmacophoric structural features for activity. Further *in* *vitro/vivo* examinations of the selected marine macrolides would pave the way towards developing effective antiviral drugs from natural resources.

**Keywords:**

SARS-CoV-2; virtual screening; molecular docking; molecular dynamics simulation; marine natural product; laulimalides marine macrolides

**1. Introduction**

The last few years have witnessed an outbreak of the new coronavirus, SARS-CoV-2 (COVID-19), correlated with human respiratory disease 1. The first case of the disease was initially identified in Wuhan, China, in December 2019 2. The symptoms were characterized by peculiar resistant pneumonia associated with elevated temperature, exhaustion, dry cough, and occasional gastrointestinal symptoms 3.

The pandemic, with its multiple variants, swiftly invaded the world, infecting more than 750 million individuals and causing deaths that exceeded 6 million cases, according to the recent WHO dashboard 4. Not only were vulnerable individuals susceptible to the infection and its consequences during the pandemic, but cases of frequent infections of vaccinated and pre-infected individuals are still being reported 5. Hence, an imperative urgency arises for tremendous efforts to be directed toward discovering and developing medicinal countermeasures to this pandemic virus, including effective prophylactic vaccines and medical treatments 6.

Nature has been considered a valuable treasure for drug discovery since antiquity 7. Intriguingly, natural products are always regarded as a backbone of traditional medicinal systems used throughout the whole world 8. Distinguished by their unique, boundless structural diversity, natural sources are endlessly inspiring for their mining for novel bioactive chemical entities 3.

Natural terrestrial plants, despite being a rich source of secondary metabolites and a major fundamental provenance for traditional folk medicine over thousands of years, their overuse made them susceptible for overharvesting, depletion, and extinction of many rare species of high medicinal value 9. On the contrary, oceans and seas covering extensive areas of the planet exceeding 70 % of the earth's surface represent a renewable, as well as, a sustainable source of bioactive natural products 10.

Besides, the marine environment, with its higher salinity, pressure, and lower temperature compared to normal conditions of terrestrial life, provoke distinctive adaptive metabolic mechanisms by the surrounding marine microorganisms ending in the production of a wide variety of natural products of significant pharmacological activities 11. Hence, the marine environment and its associated microorganisms have recently received remarkably growing attention for discovering an enormous scaffold diversity of natural products of medicinal importance 12.

Marine macrolides are considered among the distinctive classes of marine natural products that have lately been regarded as fascinating mines for drug discovery 13.

Pharmacologically, they demonstrated prominent biological activities, including antibacterial, antifungal, anti-inflammatory, cytotoxic, and antiviral potentials 14-16. Macrolides, which are being biosynthesized via the polyketide pathway, are characterized by their large macrocyclic lactone ring that is usually 14-, 15-, or 16-membered. Moreover, further, 20-,24-, 26- or 36-membered macrolides are also identified, such as oligomycin A and amphotericin B. Numerous patterns of alkylation, dehydration, and oxygenation through the polyene backbone account for the great chemical diversity among marine macrolides 15.

Laulimalides are a distinctive class of 20-membered marine macrolides that were initially isolated from the marine chocolate sponge, *Cacospongia mycofijiensis* 17.Laulimalide (also known as fijianolide) has been reported as a prominent microtubule-stabilizing agent that significantly enhances the density of interphase microtubules, elicits the generation of abnormal mitotic spindles and microtubule bundles 16, 18.

Indeed, it intensively inhibits cancer cell proliferation with notable potency against paclitaxel-resistant cells. It is also proven to possess another privilege; its superior capability of overcoming multidrug resistance emerging from P-glycoprotein 19. Structurally, the laulimalide skeleton is characterized by its two dihydropyran rings (C5-C9) and (C23-C27), attached to the macrolide skeleton via 2,6-*trans* attachment and terminal *trans*-allylic alcohol attachment, respectively. It is also distinguished by the 2,3-*cis* unsaturated double bond, the presence of nine chiral centers at positions 5*R*, 9*S*, 11*S*, 15*R*, 16*S*, 17*S*, 19*S*, 20*S*, and 23*S,* respectively, and the trans-di-substituted epoxide at position C-16 and C-17 14.

Laulimalide, under mildly acidic conditions, undergoes ring opening of the fragile C16-C17-epoxide via the nucleophilic attack of the C-20 hydroxyl group generating the less potent isomer, isolaulimalide 20. Owing to the potent activities of laulimalide and its distinguished chemical structure, multiple research groups have worked on its total synthesis and the synthesis of various analogues in an attempt to enhance its stability and bioactivity, especially under acidic conditions 21, 22. Besides, structurally simplified analogues of laulimalide were designed to reduce the cost of synthetic steps.

The groups of Ghosh, Paterson, and Mulzer accomplished the total chemical synthesis of laulimalide and a number of modified analogues 23. The elimination of C16-C17- epoxide and alkylation of C-20 hydroxyl group were among the strategies adopted in the synthesis of different laulimalide analogues, including LA1 (**3**), LA2 (**4**), LA3 (**5**) and LA4 (**6**) 16. Besides, the conversion of the C2-C3-enoate to an alkynoate evidenced in the synthesis of LA3 was an effective way to alter the orientation of the C16-C17-epoxide relative to the C20-hydroxyl.

Moreover, analogues combining the two functional group conversions were also synthetized as LA4 (**6**) and LA5 (**7**) 22. Other function-oriented synthetic studies were accomplished to investigate the effect of altering the side chain substitution attached at C-22 on the antiproliferative effectiveness of the laulimalide. The importance of the alkene pi-system inside the chain attached at C-22 in the antiproliferative effectiveness of the laulimalide was concluded from the diminished antiproliferative activity of the LA13 (**8**) analogue associated with the methyl ether attachment instead of the pyran unit.

Diminished antiproliferative potency was demonstrated with the analogues, LA14 (**9**) and LA16 (**11**), with the pyran ring substituted by cyclohexane and aryl ring, respectively. Meanwhile, epoxidized C21-C22 olefin, in LA15 (**10**), the minor side product in the synthesis of LA14 (**9**), did not show better potency than LA14 (**9**). However, the C-23-cyclohexane analogues, LA18 (**13**) and LA18` (**14**), with the unsaturated side chain, demonstrated unpredicted enhanced potency 18. In the meantime, the significant impact of computational and bioinformatics tools was conceded in the field of drug discovery 24.

Applying computer science to characterize and understand the chemical behaviour and molecular attributes of specific chemical molecules was recognized as the first crucial step in the track of discovering new lead compounds 25. Using various computational and bioinformatics tools, drug-protein interactions, the pharmacokinetics, stability, as well as toxicity of plenty of bioactive marine natural products, including laulimalides would be easily estimated and elucidated 26.

De leon *et al*., investigated a bunch of 104 anti-HIV reverse transcriptase phytochemicals for their potential inhibitory properties against seven key SARS-CoV-2 non-structural proteins (nsps) via molecular docking and molecular dynamics. Polyphenolic plant derived natural products, such as biflavones and ellagitannins, showed the strongest binding affinities, suggesting their potential as multi-target drug prototypes against COVID-19 27.

Quimque *et al*., conducted a comerhensive virtual screening strategy including molecular docking (MDock) and molecular dynamics simulations (MDS) to identify potential inhibitors of key SARS-CoV-2 enzymes responsible for viral attachment, replication, post-translational modification, and evasion of host immunity. The authors highlighted a bunch fungal-derived natural products, including quinadoline B, scedapin C, and isochaetochromin D1, with promise as multi-target inhibitors. The study highlights the potential of these compounds as drug candidates for COVID-19, warranting further validation 28.

Thus, core bridgeheads between biological effectiveness and quantitative structure-activity relationships could be consequently established 29. In this study, we comprehensively explore virtually a concise library of fourteen laulimalides marine-containing macrolides against SARS-CoV-2 main protease (Mpro) dimer using state-of-the-art integrated computational tools, including molecular docking, molecular dynamics (MD) simulations, binding free energy and SARs.

These *in- silico* methods successfully predicted novel potential inhibitors against Mpro and other drug targets of SARS-CoV-2 30-32. Continuing our ongoing strategy for identifying potential bioactive lead compounds derived from marine natural products 33, herein we investigate the antiviral potentialities of 14 laulimalide-containing macrolides (**LMM**) utilizing comprehensive virtual screening against SARS-CoV-2 main protease (Mpro).

**2. Materials and Methods**

**2.1 Ligand structures preparation**

SCIGRESS 3.0 software was utilized to draw and then minimize the structures of laulimalides (**1-14**) 34. We performed geometry optimization to ensure that the starting compounds were at their lowest energy conformation before performing the docking experiments. This is an important step when working with new compounds that have no known 3D conformations. The optimization was done in two steps.

First, the molecular mechanics' force field 3 (MM3) and the output were optimized using the semi-empirical parameterization method 6 (PM6). After that, infra-red spectra were calculated to ensure system reliability using PM6 in water method 35. Then, we also optimized the positive control compounds (O6K and N3) that we retrieved from the protein data bank (https://www.rcsb.org/) (PDB IDs: 6Y2G and 6LU7) 36, 37. After optimization, partial charges (Kollman and Gasteiger) were added using AutoDock tools 1.5.6 38. Finally, the PDBQT files of the ligands were saved to be ready for the docking experiments.

We previously simulated the Mpro (dimer conformation) of SARS-CoV-2 (PDB ID: 6Y2G) for 100 ns to study its dynamics. After that, we clustered the trajectories into five groups. We utilized representative cluster conformations of the protein in this study to test ligand binding affinities 39. The docking was performed using the five representative conformations to overcome the bias excreted by the rigid x-ray structure.

**2.2 Molecular Docking (MDocking)**

The five representative conformations of Mpro were prepared using AutoDock Tools 1.5.6 software, where missed H-atoms were added, but water and cofactors were removed. The docking was performed using AutoDock Vina 1.2.2 40. The active site dyad (H41 and C145) was treated as flexible during the docking experiments 37. Ligands were also treated as flexible in the docking protocol, where the rotamers were detected by AutoDock Tools 1.5.6 during the preparation stage. The docking box was set to cover the active site dyad centered at the residues H41 and C145 and having a size of 30 × 30 × 30 Å3. The docked complexes need to be stable during protein dynamics, so we need to check the binding affinity and interactions during protein dynamics.

**2.3 Molecular Dynamics (MD) Simulations**

MD simulations of the best two compounds-Mpro and a positive control N3-Mpro complexes, were performed by the GROMACS software utilizing the CHARMM36 force field. This was done to monitor the formed interactions between the ligands and the Mpro during the simulation period. Additionally, we will get detailed information about the binding affinity contributions from Mpro residues during the MD simulation. The input files were generated using the Charmm GUI webserver 41.

The simulation lasted for 150 ns using the TIP3P water model at 1 atm pressure and 310 K temperature. The systems were ionized with NaCl of concentration of 0.154 M 42. A cubic periodic boundary condition simulation box was utilized during the run at the NVT ensemble 43.

Simulation trajectories were then analyzed using VMD 1.9.3 software and some in-house codes 44. Furthermore, the Molecular Mechanics-Generalized Born Surface Area (MM-GBSA) was calculated for the complexes using Amber tools to deconvolute the binding affinity as a per-residue contribution and the binding energy contributions 45. The pharmacological properties of the best two hits are now important to deal with, which will be analyzed in the next section.

**2.4 *In-silico* Prediction of Physicochemical Properties, Pharmacokinetic and Toxicity Profiles**

The physicochemical properties, pharmacokinetic and toxicity profiles of the fourteen laulimalide-containing macrolides (**1**-**14**) in the selected screening library (**Scheme 1**) were calculated using the pkCSM online webtool (<http://biosig.unimelb.edu.au/pkcsm/prediction>, accessed on 24 March 2023) 46.

The pkCSM tool comprises six physicochemical properties, such as molecular weight (MW), octanol–water partition coefficient (LogP), number of rotatable bonds, number of hydrogen bond donors, number of hydrogen bond acceptors, and surface area. The pharmacokinetic profile of a compound defines its absorption, distribution, metabolism, and excretion (ADME) properties.

The pkCSM tool currently has seven available absorption properties (water solubility, Caco-2 permeability, intestinal absorption (human), skin permeability, P-glycoprotein substrate, P-glycoprotein I inhibitor, P-glycoprotein II inhibitor), four distribution properties (VDss (human), fraction unbound (human), BBB (blood-brain barrier) permeability, CNS (central nervous system) permeability), seven metabolism properties (CYP2D6 substrate, CYP3A4 substrate, CYP1A2 inhibitor, CYP2C19 inhibitor, CYP2C9 inhibitor, CYP2D6 inhibitor, CYP3A4 inhibitor), and two excretion properties (total clearance, renal OCT2 substrate).

The potential toxicity profiles of these compounds were predicted using the pkCSM, which has eight available properties: AMES toxicity, maximum tolerated dose (human), oral rat acute toxicity (LD50), oral rat chronic toxicity (LOAEL), hERG I inhibitor, hERG II inhibitor, hepatotoxicity, and skin sensitization 47.

**2.5. Identification of laulimalides Marine Macrolides**

A focused list of naturally occurring and synthetic homologues of fourteen laulimalides marine-containing macrolides (**1-14**) were selected and demonstrated as in (**Scheme 1**). Comprehensive details about their isolations, structural characterizations and synthetic preparations, were previously reported by Clark *et al.,* 17 and Mooberry *et al.,* 16, 18.



**Scheme 1**: Investigated laulimalides marine-containing macrolides (**1-14**)

**3. Results and Discussions**

**3.1** **Molecular Docking and Binding Energies Studies**

In the current study, a focused list of fourteen laulimalides marine-containing macrolides (**Scheme 1**) were *in-silico* investigated against SARS-CoV-2 Mpro*,* aiming to evaluate their binding energies and binding mode to the active site of Mpro. As previously reported, the 100 ns MDS of the Apo-Mpro was enough to equilibrate the protein system at the NVT ensemble 31. The root-mean-square fluctuations also ensured system stability during the simulation, so we used the structural conformations in the current study. Additionally, this trajectory was redocked with the positive control **O6K** and was successful with root-mean-square displacement > 1.0 Å. **Figure 1** shows the average binding energies (in Kcal/mol) for the ligands (**O6K**, **N3**, and the 14 laulimalides marine macrolides) to the Mpro active site (H41 and C145). Error bars represent the standard deviation of the mean.



Map

Description automatically generated

Map

Description automatically generated

Map

Description automatically generated

Diagram

Description automatically generated

Figure 1 The docking of the laulimalides compounds (1-14) to the SARS-CoV-2 Mpro. (A) The average binding energies calculated using AutoDock Vina software for the five different conformations with error bars represent the standard deviation. (B) The docking poses (compounds 1-14) selected for each ligand against the two positive controls, N3 and OK6 (the closest to the average binding affinity value) are predicted by the PLIP web server and drawn by PyMOL. Blue lines and dashed-gray lines represent the formed H-bonds and hydrophobic contacts.

Most compounds demonstrated lower average binding energies (more negative values) compared to the positive control (**O6K** and **N3**). Particularly, the two compounds, laulimalides LA4 (**6**) and LA18 (**13**), showed the best binding affinities to the Mpro active site with average binding energies of -8.54 ± 0.31 and -8.58 ± 0.80 Kcal/mol, respectively.

**Table 1** and **Figure 1** (**B**) summarize the formed interactions established upon docking. Most docking experiments establish two types of interactions: H-bonds and hydrophobic contacts. For the 14 compounds, the average number of formed H-bonds is 2.14, while the average number of established hydrophobic contacts is 4.57. This reflects the importance of the hydrophobic contacts in binding the ligands at the Mpro active site. This coincides with our previous findings with marine polycyclic batzelladine alkaloids that we suggested as promising inhibitors for Mpro 31.

Additionally, the hydrophobic contacts were more critical than H-bonds in Mpro binding of novel bis-[1,3,4]thiadiazolimines and bis-Thiazolimines 30.

For the best two compounds [laulimalides LA4 (**6**) and LA18 (**13**)], six hydrophobic contacts and at least one H-bond have been displayed between the ligand and the Mpro residues. The most reported residues to form hydrophobic contacts are M165, Q189, E166, M49, and C145, with the detected occurrence of 15, 13, 8, 6, and 5, respectively, while the residues H164 and Q189 (5 events each) form H-bonds upon docking.

**Table 1**: The detailed interactions established upon docking the **O6K,** **N3**, and marine macrolides (1-14) against the SARS-CoV-2 Mpro (PDB ID: 6Y2G, Chain A) retrieved from PLIP webserver and visualized by PyMOL. Bold residues are the active site dyads H41 and C145.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Ligand | Binding affinity (kcal/mol) | Hydrophobic Interactions | | H-bonds | |
| No. | Residues involved | No. | Residues involved |
| O6K | -7.08 ±0.37 | 2 | E166 and A191 | - | - |
| N3 | -6.96 ±0.42 | 2 | L4 and **C145** | 3 | N142, G143, and S301 |
| 1 | -7.70 ±0.14 | 1 | Q189 | 2 | G143 and **C145** |
| 2 | -8.32 ±0.29 | 4 | M49, **C145**, M165, and Q189 | 3 | **H41** and Q189(2) |
| 3 | -8.08 ±0.58 | 8 | T25, M49, F140, N142, **C145**, M165, E166, and Q189 | 1 | E166 |
| 4 | -7.90 ±0.34 | 4 | P39, M49, M165, and Q189 | 3 | H164 and Q192(2) |
| 5 | -7.54 ±0.67 | 4 | P39, M49, E166, and Q189 | 1 | Q189 |
| 6 | **-8.54** ±0.31 | 6 | **C145**, M165(2), L167, Q189, and Q192 | 1 | H164 |
| 7 | -8.14 ±0.21 | 4 | S1, E166, P168, and Q189 | 2 | S1\* and N142 |
| 8 | -7.12 ±0.28 | 3 | M49 and M165(2) | 5 | H163, H164, E166, R188, and Q189 |
| 9 | -7.88 ±0.47 | 4 | T25, M165, P168, and Q189 | 2 | H164 and T190 |
| 10 | -8.22 ±0.39 | 5 | T25, S46, M165, L167, and Q192 | - | - |
| 11 | -8.22 ±0.22 | 6 | M165(2), E166(2), Q189, and A191 | 2 | **H41** and Q189 |
| 12 | -7.48 ±0.17 | 6 | M165, E166, P168, Q189(2), and A191 | 3 | G143, S144, and **C145** |
| 13 | **-8.58** ±0.80 | 6 | M49, **C145**, M165, E166, and Q189(2) | 4 | G143, **C145**, H164, and E166 |
| 14 | -8.08 ±0.61 | 3 | M165(2) and Q192 | 1 | N142 |

\* The interaction occurred between the compound and Chain B of the Mpro.

The best two chemical hints [laulimalides LA4 (**6**) and LA18 (**13**)] complexed with Mpro are subjected to a 150 ns MDS run to quantify their binding energies further. Additionally, the complex of N3-Mpro was also simulated for comparison.

**3.2 Molecular Dynamic Simulation (MDS)**

**Figure 2** shows MDS analysis where the protein backbone root-mean-square deviation (RMSD) in Å (A), ligand-RMSD in Å (B), the radius of gyration (RoG) in Å (C), surface accessible surface area (SASA) in nm2 (D), the number of total H-bonds (E), and the protein-ligand H-bonds (F) are plotted against the simulation time in ns. Additionally, the per-residue root-mean-square fluctuations (RMSF) in Å for Chain A (upper) and Chain B (lower) are plotted in **Figure 2G**. The **N3**, laulimalide LA4 (**6**), and laulimalide LA18 (**13**) are shown in gray, blue, and orange lines in **Figure 2**.

All three systems were equilibrated after 60 ns (around 2 Å) with a slight elevation of the RMSD values for laulimalide LA4 (**6**), and laulimalide LA18 (**13**) (2.2 and 2.0 Å) compared to the positive control **N3** (1.6 Å). On the other hand, the ligand-RMSD exhibits the opposite pattern, where the positive control **N3** shows slightly higher values (4.0 Å) compared to laulimalide LA4 (**6**) (2.8 Å) and laulimalide LA18 (**13**) (1.8 Å). The three systems were stable during the simulation, as reflected by the RoG, SASA, and the total number of H-bonds (protein backbone) in **Figures 2C-2E**.

The curves coincide and fluctuate around 26.1 Å, 270 nm2, and 440 for the RoG, SASA, and total H-bonds, respectively. The protein-ligand H-bonds also reflect systems stability during the simulation as the number of H-bonds fluctuates between 1 and 3 in most frames of the three trajectories. RMSF in **Figure 2G** of the Mpro complexes with [**N3** (gray), laulimalides LA4 (**6**) (blue), and LA18 (**13**) (orange)] for chain A (upper) and chain B (lower) show identical behavior previously reported with other complexes 48.

Only one region of moderate fluctuations was reported for residues centered around 48, reflecting the flexibility of the loop I43-P52. Additionally, the protein terminals are flexible, but other regions show low fluctuations in all the complexes (RMSF > 3 Å).

The MM-GBSA calculated for the binding energies of the positive control N3 (gray), [laulimalides LA4 (**6**) (blue), and LA18 (**13**) (orange)] to Mpro is shown in **Figure 2H**. The error bars represent the standard deviation for each value. The average binding energies of laulimalide LA4 (**6**) (-9.91 ±8.1 Kcal/mol) did not significantly differ from the positive control **N3**. On the other hand, laulimalide LA18 (**13**) 's average binding energy value (-20.51 ±6.1 Kcal/mol) is lower than that of the positive control (-16.31 ±8.5 Kcal/mol). This reflects the potential of the laulimalide LA18 (**13**) to bind to and hence inhibit Mpro, which is yet to be verified experimentally.

Chart, line chart

Description automatically generated

Chart, line chart

Description automatically generated

Chart, line chart

Description automatically generated

Chart, line chart

Description automatically generatedChart

Description automatically generated

Chart, bar chart

Description automatically generated

Graphical user interface, application, histogram

Description automatically generated

Chart, box and whisker chart

Description automatically generated

Figure 2 Molecular Dynamics Simulation trajectory analysis for the complexes of Mpro with N3 (gray), laulimalides LA4 (6) (blue), and LA18 (13) (orange). A) The protein backbone Root-mean-square deviation (RMSD) in Å versus the simulation time in ns. B) The ligand-protein RMSD in Å versus the simulation time in ns. C) The Radius of Gyration (RoG) in Å versus the simulation time in ns. D) Surface Accessible Surface Area (SASA) in nm2 versus the simulation time in ns. E) The number of total H-bonds versus the simulation time in ns. F) The protein-ligand H-bonds versus the simulation time in ns. G) The per-residue root-mean-square fluctuations (RMSF) in Å for the two chains of the dimeric Mpro. H) The calculated MM-GBSA for the three complexes after the dynamics in kcal/mol. Error bars represent the standard deviation.

**4. Structure-Binding Affinity Relationships**

All fourteen investigated laulimalide-containing macrolides (**1**-**14**), shown in (**Scheme 1)**, share a common 20-membered structure containing eight chiral centers (5*R*, 9*S*, 11*S*, 15*S*, 16*S*, 17*S*, 19*S*, 20*S*) highlighted in blue, as shown in (**Figure 3**), and with predicted free binding energies (∆GB) ranging from -8.58 Kcal/mol to -7.12 Kcal/mol (**Table 1**). Seven of them possess the core structure of laulimalide (**1**) only changing the C-23 side chain (**8**-**9**,**11**-**14**), between a methoxy group in LA13 (**8**), a cyclohexane ring in LA14 (**9**), a phenyl ring in LA16 (**11**), a dioxolane ring in LA17 (**12**) and a cyclohexene ring in LA18 (**13**) and LA19 (**14**), with predicted ∆GB between -8.58 and -7.12 Kcal/mol (Table 1). Derivatives LA18 (**13**) and LA19 (**14**) are diastereoisomers, differing only in the configuration of the C-23 chiral center, 23*S* in LA18 (**13**) like laulimalide (**1**) and 23*R* in LA19 (**14**), with predicted ∆GB of -8.58 and -8.08 Kcal/mol, respectively.



*Figure 3. Common structural core with numeration of laulimalides*

In LA2 (**4**), only the substituent at position C-20 has changed from a hydroxyl group in laulimalide (**1**) to a methoxyl group in LA2 (**4**), with a predicted ∆GB of -7.90 Kcal/mol. There are three derivatives (**3**, **6**, **7**) in which depoxidation occurs at positions C-16 and C-17, as compared to laulimalide (**1**): LA3 (**3**) has the same substitution pattern as laulimalide (**1**), LA4 (**6**) has a methoxy group at position 20, and LA5 (**7**) has a triple bond at positions 2 and 3, with predicted free binding energies of -8.08, -8.54, and -8.14 Kcal/mol, respectively.

Finally, isolaulimalide (**2**) is an isomer of laulimalide (**1**), the tetrahydrofuran ring of which is formed by an SN2-type attack of the C-20 hydroxygroup at the C-17 position of the epoxide in laulimalide (**1**), with a predicted ∆GB of -8.32 Kcal/mol, compared with -7.70 Kcal/mol for laulimalide (**1**) . In the same way as has been reported for anti-cancer activity 49, the lack of the epoxide moiety at the C-16 and C-17 positions in isolaulimalide (**2**) and LA1 (**3**) does not translate into an increase in the predicted ∆GB, which suggests that the epoxide moiety of laulimalide may not be an essential feature for the activity against SARS-CoV-2 Mpro. As can be seen by the ∆GB calculated values for the isolaulimalide (**2**) and LA1 (**3**) of -8.32 Kcal/mol and -8.08 Kcal/mol (**Table 1**), respectively, compared to -7.70 Kcal/mol for laulimalide (**1**) .

The substitution of the C-20 hydroxyl group with the C-20 methoxyl group appears to favor the activity against SARS-CoV-2 Mpro, as can be seen in a decrease in the ∆GB calculated in the C-20 methoxylated derivatives LA2 (**4**) and LA4 (**6**) of -7.9 and -8.54 Kcal/mol, respectively, when compared to the C-20 hydroxylated derivatives laulimalide (**1**) and LA1 (**3**) of -7.7 and -8.08 Kcal/mol, respectively. The substitution of the 2,3-*Z*-double bond for a triple bond in the derivatives LA3 (**5**) and LA5 (**7**) with ∆GB values of -7.54 and -8.14 Kcal/mol, respectively, does not result in a significant variation of the predicted ∆GB when compared to the corresponding derivatives with the double bond, laulimalide (**1**) and LA1 (**3**), with ∆GB values of -7.7 and -8.08 Kcal/mol, respectively.

The C-23 side chain (derivatives **8**-**9**, **11**-**14**) appears to be very relevant for the activity against SARS-CoV-2 Mpro in accordance with previously reported anti-cancer activity 49, 50. The structural variation in the C-23 side chain includes: (I) oxygen-containing substituents such as dihydropyran (**1**), methoxy (**8**) and 1,3-dioxalane (**12**) with calculated ∆GB of -7.7, -7.12 and -7.48 Kcal/mol, respectively ; (II) carbon 6-membered rings such as cyclohexane (**9**), phenyl (**11**) and cyclohexene (**13** and **14**) with calculated ∆GB of -7.88, -8.22, -8.58 and -8.08 Kcal/mol, respectively. The C-23 configuration also appears to be extremely important for activity, as can be seen in the ΔGB calculated for epimers LA18 (**13**) and LA19 (**14**) of -8.58 and -8.08 Kcal/mol, respectively. Epoxidation of the *trans*-21,22 double bond also translates into a decrease in the calculated ∆GB value of -8.22 Kcal/mol for LA15 (**10**) compared to -7.88 Kcal/mol for LA14 (**9**).

**5.** **Druglikeness and Pharmacokinetics**

To evaluate the druglikeness behaviour of the fourteen investigated laulimalide-containing macrolides (**1**-**14**), the Lipinski's Rule of five was applied based on the physicochemical properties predicted by the pkCSM tool. It is observed that only the derivative LA4 (**6**) fails two of the four Lipinski's rules (MW and LogP). There are seven derivatives that fail one of the Lipinski's rules (MW): laulimalide (**1**), isolaulimalide (**2**), LA2 (**4**), LA3 (**5**), LA14 (**9**), LA15 (**10**) and LA16 (**11**), (**Figure 4**). The remaining six derivatives do not fail any of the Lipinski's rules, (**Figure 4**). All laulimalide-containing macrolides were predicted with an adequate pharmacokinetic profile taking into account the ADME properties. In **Figure 4**, we highlight twelve of the thirteen laulimalide derivatives that are predicted to cross the blood-brain barrier (BBB) with normal or low permeability. These twelve derivatives (**1**-**7**, **9**-**11**, **13**, and **14**) are located in the yellow region of the BOILED-Egg model in Figure 4. Only derivative (**8**), predicted to cross the BBB with low permeability, is mapped in the white part of the egg. Interestingly, among all the laulimalide derivatives, only derivative (**8**) is predicted to have low Caco-2 permeability, while the others are predicted to have high permeability. The compounds located in the egg white, including laulimalide derivative (**12**) and the three positive controls (**O6K**, **N3**, and **Paxlovid**), are predicted to be non-permeable to the BBB. Furthermore, all 14 laulimalide derivatives and the three positive controls are predicted to be absorbed in the human intestine.

**Figure 4.** BOILED-Egg plot. Whrere: MW (molecular weight), LogP (octanol–water partition coefficient), NP(Non-Penetrable), LP (Low Penetrable), P (Penetrable). The Lipinski's rule violations are shown as red dash lines.

Considering the toxicological prediction profile, only hepatotoxicity issues were raised for nine derivatives, including laulimalide (**1**), isolaulimalide (**2**), LA1 (**3**), LA3 (**5**), LA4 (**6**), LA5 (**7**), LA16 (**11**), LA18 (**13**) and LA19 (**14**). Regarding the two macrolides, LA4 (**6**) and LA18 (**13**), predicted as the most promising inhibitors against SARS-CoV-2 Mpro, only laulimalide, LA4 (**6**), was predicted to have hepatotoxicity. Although both promising laulimalides, LA4 (**6**) and LA18 (**13**), are predicted to be non-inhibitors of cytochrome P450 isoforms (CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4), an important class of detoxification enzymes primarily found in the liver.

Our study are based solely on the viral protein Mpro which is the main viral protease crucial in the replication cycle of the SARS-CoV-2 but not the only protease that should be targeted. Another viral protease, the papin-like (PLpro) should be tested against these Laulimalides for further understand the mechanism of inhibition on SARS-CoV-2 excerted by Laulimalides. This is suggested as future work along with experimental validation.

**6. Conclusions**

An integrated array of computational tools comprising MDock, MD, and SARs studies were manipulated for investigating the binding affinities of a total of 14 laulimalide- containing marine macrolides (**LMM**) against the SARS-CoV-2 main protease (Mpro) dimer. Interestingly, the molecular docking and binding energy studies demonstrated promising binding capabilities of the different laulimalide ligands with average binding energies less than that demonstrated by the positive controls, [**O6K** and **N3**]. Best binding affinities to the Mpro active site were manifested by the laulimalides, LA4 (**6**) and LA18 (**13**), which showed average binding energies of less than -8 kcal/mol. Moreover, stable molecular dynamics within the accommodated (Mpro) pockets were demonstrated by the most potent laulimalides, LA4 (**6**) and LA18 (**13**).

To explore the link between the chemical structure of the assessed laulimalides and the generated suggested activity, a preliminary structure-activity relationship study was performed. Results demonstrated the crucial role of the C-23 side chain in influencing the activity against SARS-CoV-2 Mpro. Besides, the C-20 methoxyl group proved to enhance the laulimalide activity. Druglikeness and pharmacokinetics studies assured the adequate physicochemical and pharmacokinetic profiles of the evaluated laulimalides with some attributes with the hepatotoxicity of certain derivatives. In conclusion, the evaluated set of laulimalide derivatives could be regarded as promising leads for combating COVID-19. Further *in vitro* and *in vivo* assays are highly recommended for better investigation of the promising activities of laulimalide derivatives, particularly for LA4 **(6)** and LA18 **(13)**, before proceeding to clinical trials.

**Authorship contribution statement**

**Conceptualization**: Abdo A. Elfiky and Amr El-Demerdash. **Validation**: Abdo A. Elfiky, Amr El-Demerdash. **Formal analysis**: Abdo A. Elfiky, Alaa M. Elgohary, Florbela Pereira, and Amr El-Demerdash. **Investigation**: Abdo A. Elfiky, Alaa M. Elgohary, Florbela Pereira and Amr El-Demerdash. **Resources**: Abdo A. Elfiky, Alaa M. Elgohary, Florbela Pereira, Mariam I. Gamal El-Din, Mohamed. A. Tammam and Amr El-Demerdash. **Data curation**: Abdo A. Elfiky, Alaa M. Elgohary, Florbela Pereira and Amr El-Demerdash. **Writing original draft**: Abdo A. Elfiky, Alaa M. Elgohary, Florbela Pereira, Mariam I. Gamla El-Din, Mohamed. A. Tammam, and Amr El-Demerdash. **Writing-review & editing**: Abdo A. Elfiky, Alaa M. Elgohary, Florbela Pereira, Mariam I. Gamla El-Din, Mohamed. A. Tammam, Adnane Aouidate and Amr El-Demerdash.

**Declaration of competing interest**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

**Using of Artificial intelligence**

I hereby confirm that no artificial intelligence or machine learning tools were used in the conception, design, or analysis of this research, except for the computational chemistry work, which included molecular docking and molecular dynamics simulations

**Data Availability**

All data generated or analysed during this study are included in this published article.

**Funding**

Amr El-Demerdash is immensely grateful to the John Innes Centre, Norwich Research Park, United Kingdom, for the postdoctoral fellowship. Florbela Pereira would like to thank Fundacão para a Ciência e a Tecnologia, MCTES, in the scope of the project UIDB/50006/2020 of the Research Unit, Associate Laboratory for Green Chemistry, LAQV".

**Acknowledgments**

We thank ChemAxon Ltd. for access to JChem and Marvin. Bibliotheca Alexandrina's high-performance computing facility (Bib Alex) was utilized for the MD simulations. Mr. Jameel Abdeljalil is thankful for his assistance with the MD calculations.

**References**

(1) Zhou, Y.; Zhi, H.; Teng, Y. The outbreak of SARS‐CoV‐2 Omicron lineages, immune escape, and vaccine effectivity. *Journal of Medical Virology* **2023**, *95* (1), e28138.

(2) Zheng, R.; Xu, Y.; Wang, W.; Ning, G.; Bi, Y. Spatial transmission of COVID-19 via public and private transportation in China. *Travel medicine and infectious disease* **2020**, *34*, 101626.

(3) Alimohamadi, Y.; Sepandi, M.; Taghdir, M.; Hosamirudsari, H. Determine the most common clinical symptoms in COVID-19 patients: a systematic review and meta-analysis. *Journal of preventive medicine and hygiene* **2020**, *61* (3), E304.

(4) <https://covid19.who.int/WHO> . Coronavirus (COVID-19) Dashboard. World Health Organization. 6/3/2023. (accessed. Pan, Y.; Wang, L.; Feng, Z.; Xu, H.; Li, F.; Shen, Y.; Zhang, D.; Liu, W. J.; Gao, G. F.; Wang, Q. Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis. *The Lancet* **2023**.

(5) Tan, S. T.; Kwan, A. T.; Rodríguez-Barraquer, I.; Singer, B. J.; Park, H. J.; Lewnard, J. A.; Sears, D.; Lo, N. C. Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave. *Nature Medicine* **2023**, 1-8.

(6) Ng, T. I.; Correia, I.; Seagal, J.; DeGoey, D. A.; Schrimpf, M. R.; Hardee, D. J.; Noey, E. L.; Kati, W. M. Antiviral drug discovery for the treatment of COVID-19 infections. *Viruses* **2022**, *14* (5), 961.

(7) El-Din, M. I. G.; Youssef, F. S. Non-Food Applications of Coriander Seed Extracts. In *Handbook of Coriander (Coriandrum sativum)*, CRC Press, pp 545-558. Ghareeb, M. A.; Tammam, M. A.; El-Demerdash, A.; Atanasov, A. G. Insights about clinically approved and Preclinically investigated marine natural products. *Current Research in Biotechnology* **2020**, *2*, 88-102.

(8) El-Din, M. I. G.; George, M. Y.; Youssef, F. S. Chemical characterization of the polyphenolic rich fraction of Thunbergia erecta and its therapeutic potential against doxorubicin and cyclophosphamide-induced cognitive impairment in rats. *Journal of Ethnopharmacology* **2023**, *307*, 116213.

(9) Uzma, F.; Mohan, C. D.; Siddaiah, C. N.; Chowdappa, S. Endophytic fungi: promising source of novel bioactive compounds. *Advances in endophytic fungal research: present status and future challenges* **2019**, 243-265.

(10) Cheng, L.; Mishra, H. Why did only one genus of insects, Halobates, take to the high seas? *PLoS Biology* **2022**, *20* (4), e3001570.

(11) Ma, H.-G.; Liu, Q.; Zhu, G.-L.; Liu, H.-S.; Zhu, W.-M. Marine natural products sourced from marine-derived Penicillium fungi. *Journal of asian natural Products research* **2016**, *18* (1), 92-115.

(12) Carroll, A. R.; Copp, B. R.; Davis, R. A.; Keyzers, R. A.; Prinsep, M. R. Marine natural products. *Natural product reports* **2022**, *39* (6), 1122-1171.

(13) Das, R.; Rauf, A.; Mitra, S.; Emran, T. B.; Hossain, M. J.; Khan, Z.; Naz, S.; Ahmad, B.; Meyyazhagan, A.; Pushparaj, K. Therapeutic potential of marine macrolides: An overview from 1990 to 2022. *Chemico-Biological Interactions* **2022**, 110072.

(14) Qi, Y.; Ma, S. The medicinal potential of promising marine macrolides with anticancer activity. *ChemMedChem* **2011**, *6* (3), 399-409.

(15) Zhang, H.; Zou, J.; Yan, X.; Chen, J.; Cao, X.; Wu, J.; Liu, Y.; Wang, T. Marine-derived macrolides 1990–2020: An overview of chemical and biological diversity. *Marine Drugs* **2021**, *19* (4), 180.

(16) Mooberry, S. L.; Randall-Hlubek, D. A.; Leal, R. M.; Hegde, S. G.; Hubbard, R. D.; Zhang, L.; Wender, P. A. Microtubule-stabilizing agents based on designed laulimalide analogues. *Proceedings of the National Academy of Sciences* **2004**, *101* (23), 8803-8808.

(17) Clark, E. A.; Hills, P. M.; Davidson, B. S.; Wender, P. A.; Mooberry, S. L. Laulimalide and synthetic laulimalide analogues are synergistic with paclitaxel and 2-methoxyestradiol. *Mol. Pharm.* **2006**, *3* (4), 457-467.

(18) Mooberry, S. L.; Tien, G.; Hernandez, A. H.; Plubrukarn, A.; Davidson, B. S. Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents. *Cancer Res.* **1999**, *59* (3), 653-660.

(19) Liu, J.; Towle, M. J.; Cheng, H.; Saxton, P.; Reardon, C.; Wu, J.; Murphy, E. A.; Kuznetsov, G.; Johannes, C. W.; Tremblay, M. R. In vitro and in vivo anticancer activities of synthetic (-)-laulimalide, a marine natural product microtubule stabilizing agent. *Anticancer research* **2007**, *27* (3B), 1509-1518. Churchill, C. D.; Klobukowski, M.; Tuszynski, J. A. Analysis of the binding mode of laulimalide to microtubules: Establishing a laulimalide–tubulin pharmacophore. *Journal of Biomolecular Structure and Dynamics* **2016**, *34* (7), 1455-1469.

(20) Wender, P. A.; Verma, V. A.; Paxton, T. J.; Pillow, T. H. Function-oriented synthesis, step economy, and drug design. *Accounts of chemical research* **2008**, *41* (1), 40-49.

(21) Gollner, A.; Mulzer, J. Total synthesis of neolaulimalide and isolaulimalide. *Organic Letters* **2008**, *10* (20), 4701-4704.

(22) Wender, P. A.; Hegde, S. G.; Hubbard, R. D.; Zhang, L.; Mooberry, S. L. Synthesis and biological evaluation of (−)-laulimalide analogues. *Organic Letters* **2003**, *5* (19), 3507-3509.

(23) Ghosh, A. K.; Wang, Y. Total synthesis of (−)-laulimalide. *Journal of the American Chemical Society* **2000**, *122* (44), 11027-11028. Paterson, I.; De Savi, C.; Tudge, M. Total synthesis of the microtubule-stabilizing agent (−)-laulimalide. *Organic Letters* **2001**, *3* (20), 3149-3152. Mulzer, J.; Öhler, E. Microtubule-stabilizing marine metabolite laulimalide and its derivatives: synthetic approaches and antitumor activity. *Chemical reviews* **2003**, *103* (9), 3753-3786.

(24) Romano, J. D.; Tatonetti, N. P. Informatics and computational methods in natural product drug discovery: a review and perspectives. *Frontiers in genetics* **2019**, *10*, 368.

(25) Gamal El-Din, M. I.; Youssef, F. S.; Altyar, A. E.; Ashour, M. L. GC/MS Analyses of the essential oils obtained from different jatropha species, their discrimination using chemometric analysis and assessment of their antibacterial and anti-biofilm activities. *Plants* **2022**, *11* (9), 1268. Gamal El-Din, M. I.; Youssef, F. S.; Ashour, M. L.; Eldahshan, O. A.; Singab, A. N. B. Comparative analysis of volatile constituents of Pachira aquatica Aubl. and Pachira glabra Pasq., their anti-Mycobacterial and anti-Helicobacter pylori activities and their metabolic discrimination using chemometrics. *Journal of Essential Oil Bearing Plants* **2018**, *21* (6), 1550-1567. El-Demerdash, A.; Hassan, A.; Abd El-Aziz, T. M.; Stockand, J. D.; Arafa, R. K. Marine brominated tyrosine alkaloids as promising inhibitors of SARS-CoV-2. *Molecules* **2021**, *26* (20), 6171.

(26) Amr, E.-D.; Ahmed, M.; Metwaly, T. M.; El-Aziz, A.; Ibrahim, H.; Eissa, J. D. Comprehensive Virtual Screening of the Antiviral Potentialities of Marine Polycyclic Guanidine Alkaloids against SARS-CoV-2 (Covid-19)(preprint). **2020**. Hassan, S. S.; Aljabali, A. A.; Panda, P. K.; Ghosh, S.; Attrish, D.; Choudhury, P. P.; Seyran, M.; Pizzol, D.; Adadi, P.; Abd El-Aziz, T. M. A unique view of SARS-CoV-2 through the lens of ORF8 protein. *Computers in biology and medicine* **2021**, *133*, 104380.

(27) de Leon, V. N. O.; Manzano, J. A. H.; Pilapil, D. Y. H.; Fernandez, R. A. T.; Ching, J. K. A. R.; Quimque, M. T. J.; Agbay, J. C. M.; Notarte, K. I. R.; Macabeo, A. P. G. Anti-HIV reverse transcriptase plant polyphenolic natural products with in silico inhibitory properties on seven non-structural proteins vital in SARS-CoV-2 pathogenesis. *Journal of Genetic Engineering and Biotechnology* **2021**, *19* (1), 104. DOI: 10.1186/s43141-021-00206-2.

(28) Quimque, M. T. J.; Notarte, K. I. R.; Fernandez, R. A. T.; Mendoza, M. A. O.; Liman, R. A. D.; Lim, J. A. K.; Pilapil, L. A. E.; Ong, J. K. H.; Pastrana, A. M.; Khan, A.; et al. Virtual screening-driven drug discovery of SARS-CoV2 enzyme inhibitors targeting viral attachment, replication, post-translational modification and host immunity evasion infection mechanisms. *Journal of Biomolecular Structure and Dynamics* **2021**, *39* (12), 4316-4333. DOI: 10.1080/07391102.2020.1776639.

(29) Pereira, F.; Bedda, L.; Tammam, M. A.; Alabdullah, A. K.; Arafa, R. K.; El-Demerdash, A. Investigating the Antiviral Therapeutic Potentialities of Marine Polycyclic Lamellarin Pyrrole Alkaloids as Promising Inhibitors for SARS-CoV-2 and Zika Main Proteases (Mpro). **2022**. Elgohary, A. M.; Elfiky, A. A.; Pereira, F.; Abd El-Aziz, T. M.; Sobeh, M.; Arafa, R. K.; El-Demerdash, A. Investigating the Structure-Activity Relationship of Marine Polycyclic Batzelladine Alkaloids as Promising Inhibitors for SARS-CoV-2 Main Protease (Mpro). *Computers in biology and medicine* **2022**, *147*, 105738.

(30) Gomha, S. M.; Riyadh, S. M.; Abdellattif, M. H.; Abolibda, T. Z.; Abdel-aziz, H. M.; Nayl, A. A.; Elgohary, A. M.; Elfiky, A. A. Synthesis and In Silico Study of Some New bis-[1,3,4]thiadiazolimines and bis-Thiazolimines as Potential Inhibitors for SARS-CoV-2 Main Protease. *Current Issues in Molecular Biology* **2022**, *44* (10), 4540-4556.

(31) Elgohary, A. M.; Elfiky, A. A.; Pereira, F.; Abd El-Aziz, T. M.; Sobeh, M.; Arafa, R. K.; El-Demerdash, A. Investigating the structure-activity relationship of marine polycyclic batzelladine alkaloids as promising inhibitors for SARS-CoV-2 main protease (Mpro). *Computers in biology and medicine* **2022**, *147*, 105738. DOI: <https://doi.org/10.1016/j.compbiomed.2022.105738>.

(32) Elfiky, A. A.; Ibrahim, I. M.; Ibrahim, M. N.; Elshemey, W. M. Host-cell recognition of SARS-CoV-2 spike receptor binding domain from different variants. *Journal of Infection* **2022**, *85* (6), 702-769. DOI: 10.1016/j.jinf.2022.10.009 (acccessed 2023/02/03). Almutairi, F. M.; Mohareb, R. M.; Elfiky, A. A.; Mahmoud, M. A. A.; Wardakhan, W. W.; Mohamed, M. S.; Abdelhameed, A. S. Synthesis, Molecular Docking, c-Met inhibitions of 2,2,2-Trichloro-ethylidene-cyclohexane-1,3-dione Derivatives Together With Their Application as Target SARS-CoV-2 main Protease (Mpro) And as Potential Anti-Covid-19. *Comb Chem High Throughput Screen* **2022**. DOI: 10.2174/1386207325666220829111236 PubMed. Ibrahim, I. M.; Elfiky, A. A.; Fathy, M. M.; Mahmoud, S. H.; ElHefnawi, M. Targeting SARS-CoV-2 endoribonuclease: a structure-based virtual screening supported by in vitro analysis. *Scientific Reports* **2022**, *12* (1), 13337. DOI: 10.1038/s41598-022-17573-6. Moriou, C.; Lacroix, D.; Petek, S.; El-Demerdash, A.; Trepos, R.; Leu, T. M.; Florean, C.; Diederich, M.; Hellio, C.; Debitus, C.; et al. Bioactive Bromotyrosine Derivatives from the Pacific Marine Sponge Suberea clavata (Pulitzer-Finali, 1982). *Mar. Drugs* **2021**, *19* (3), 143.

(33) El-Demerdash, A.; Atanasov, A. G.; Horbanczuk, O. K.; Tammam, M. A.; Abdel-Mogib, M.; Hooper, J. N.; Sekeroglu, N.; Al-Mourabit, A.; Kijjoa, A. Chemical diversity and biological activities of marine sponges of the genus Suberea: A systematic review. *Marine drugs* **2019**, *17* (2), 115. El-Demerdash, A.; Metwaly, A. M.; Hassan, A.; Abd El-Aziz, T. M.; Elkaeed, E. B.; Eissa, I. H.; Arafa, R. K.; Stockand, J. D. Comprehensive virtual screening of the antiviral potentialities of marine polycyclic guanidine alkaloids against SARS-CoV-2 (COVID-19). *Biomolecules* **2021**, *11* (3), 460. Tammam, M. A.; El-Din, M. I. G.; Abood, A.; El-Demerdash, A. Recent Advances in Discovery, Biosynthesis and Therapeutic Potentialities of Isocoumarins Derived from Fungi: A Comprehensive Update. *RSC Advances* **2023**, *13*, 8049 - 8089. El-Demerdash, A.; Petek, S.; Debitus, C.; Al-Mourabit, A. Crambescidin Acid from the French Polynesian Monanchora n. sp. Marine Sponge. *Chem. Nat. Compd.* **2020**, *56* (6), 1180-1182. DOI: 10.1007/s10600-020-03262-1. El-Demerdash, A.; Ermolenko, L.; Gros, E.; Retailleau, P.; Thanh, B. N.; Anne, G.-B.; Al-Mourabit, A. Short-Cut Bio-Inspired Synthesis of Tricyclic Guanidinic Motifs of Crambescidins and Batzelladines Marine Alkaloids. *Eur. J. Org. Chem. n/a* (n/a). DOI: 10.1002/ejoc.202000744.

(34) Elfiky, A. A.; A., G. W.; M., E. W. Hepatitis C Viral Polymerase Inhibition using Directly Acting Antivirals, A Computational Approach. In *Software and Techniques for Bio-Molecular Modeling*; A, M., Ed.; Austin publishing group, 2016; p 197. Summers, K. L.; Mahrok, A. K.; Dryden, M. D.; Stillman, M. J. Structural properties of metal-free apometallothioneins. *Biochem Biophys Res Commun* **2012**, *425* (2), 485-492. DOI: 10.1016/j.bbrc.2012.07.141.

(35) Bikadi, Z.; Hazai, E. Application of the PM6 semi-empirical method to modeling proteins enhances docking accuracy of AutoDock. *J Cheminform* **2009**, *1* (1), 15. DOI: 10.1186/1758-2946-1-15.

(36) Zhang, L.; Lin, D.; Sun, X.; Curth, U.; Drosten, C.; Sauerhering, L.; Becker, S.; Rox, K.; Hilgenfeld, R. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved &#x3b1;-ketoamide inhibitors. *Science* **2020**, *368* (6489), 409-412. DOI: doi:10.1126/science.abb3405. Sussman, J. L.; Lin, D.; Jiang, J.; Manning, N. O.; Prilusky, J.; Ritter, O.; Abola, E. E. Protein Data Bank (PDB): database of three-dimensional structural information of biological macromolecules. *Acta Crystallogr D Biol Crystallogr* **1998**, *54* (Pt 6 Pt 1), 1078-1084. DOI: 10.1107/s0907444998009378.

(37) Jin, Z.; Du, X.; Xu, Y.; Deng, Y.; Liu, M.; Zhao, Y.; Zhang, B.; Li, X.; Zhang, L.; Peng, C.; et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. *Nature* **2020**, *582* (7811), 289-293. DOI: 10.1038/s41586-020-2223-y.

(38) Morris, G. M.; Huey, R.; Lindstrom, W.; Sanner, M. F.; Belew, R. K.; Goodsell, D. S.; Olson, A. J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *J Comput Chem* **2009**, *30* (16), 2785-2791. DOI: 10.1002/jcc.21256 PMC.

(39) Elgohary, A. M.; Elfiky, A. A.; Pereira, F.; Abd El-Aziz, T. M.; Sobeh, M.; Arafa, R. K.; El-Demerdash, A. Investigating the structure-activity relationship of marine polycyclic batzelladine alkaloids as promising inhibitors for SARS-CoV-2 main protease (M(pro)). *Computers in biology and medicine* **2022**, *147*, 105738. DOI: 10.1016/j.compbiomed.2022.105738 From NLM.

(40) Trott, O.; Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J Comput Chem* **2010**, *31* (2), 455-461. DOI: 10.1002/jcc.21334.

(41) Lee, J.; Cheng, X.; Swails, J. M.; Yeom, M. S.; Eastman, P. K.; Lemkul, J. A.; Wei, S.; Buckner, J.; Jeong, J. C.; Qi, Y.; et al. CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM Simulations Using the CHARMM36 Additive Force Field. *J Chem Theory Comput* **2016**, *12* (1), 405-413. DOI: 10.1021/acs.jctc.5b00935.

(42) Harrach, M. F.; Drossel, B. Structure and dynamics of TIP3P, TIP4P, and TIP5P water near smooth and atomistic walls of different hydroaffinity. *J Chem Phys* **2014**, *140* (17), 174501. DOI: 10.1063/1.4872239. Mark, P.; Nilsson, L. Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K. *The Journal of Physical Chemistry A* **2001**, *105* (43), 9954-9960.

(43) Phillips, J. C.; Braun, R.; Wang, W.; Gumbart, J.; Tajkhorshid, E.; Villa, E.; Chipot, C.; Skeel, R. D.; Kale, L.; Schulten, K. Scalable molecular dynamics with NAMD. *J Comput Chem* **2005**, *26* (16), 1781-1802. DOI: 10.1002/jcc.20289.

(44) Humphrey, W.; Dalke, A.; Schulten, K. VMD: visual molecular dynamics. *Journal of molecular graphics* **1996**, *14* (1), 33-38, 27-38. DOI: 10.1016/0263-7855(96)00018-5 From NLM. Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. UCSF Chimera—a visualization system for exploratory research and analysis. *Journal of computational chemistry* **2004**, *25* (13), 1605-1612.

(45) Genheden, S.; Ryde, U. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. *Expert Opin Drug Discov* **2015**, *10* (5), 449-461. DOI: 10.1517/17460441.2015.1032936. Miller, B. R., 3rd; McGee, T. D., Jr.; Swails, J. M.; Homeyer, N.; Gohlke, H.; Roitberg, A. E. MMPBSA.py: An Efficient Program for End-State Free Energy Calculations. *J Chem Theory Comput* **2012**, *8* (9), 3314-3321. DOI: 10.1021/ct300418h.

(46) Pires, D. E. V.; Blundell, T. L.; Ascher, D. B. pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. *Journal of medicinal chemistry* **2015**, *58* (9), 4066-4072. DOI: 10.1021/acs.jmedchem.5b00104.

(47) Daina, A.; Michielin, O.; Zoete, V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Scientific Reports* **2017**, *7* (1), 42717. DOI: 10.1038/srep42717. Baell, J. B.; Holloway, G. A. New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays. *J. Med. Chem.* **2010**, *53* (7), 2719-2740. DOI: 10.1021/jm901137j.

(48) Adem, Ş.; Eyupoglu, V.; Ibrahim, I. M.; Sarfraz, I.; Rasul, A.; Ali, M.; Elfiky, A. A. Multidimensional in silico strategy for identification of natural polyphenols-based SARS-CoV-2 main protease (Mpro) inhibitors to unveil a hope against COVID-19. *Computers in biology and medicine* **2022**, *145*, 105452. DOI: <https://doi.org/10.1016/j.compbiomed.2022.105452>.

(49) Cao, Y.-N.; Zheng, L.-L.; Wang, D.; Liang, X.-X.; Gao, F.; Zhou, X.-L. Recent advances in microtubule-stabilizing agents. *Eur. J. Med. Chem.* **2018**, *143*, 806-828.

(50) Morris, J. D.; Takahashi-Ruiz, L.; Persi, L. N.; Summers, J. C.; McCauley, E. P.; Chan, P. Y.; Amberchan, G.; Lizama-Chamu, I.; Coppage, D. A.; Crews, P. Re-evaluation of the Fijianolide/Laulimalide Chemotype Suggests an Alternate Mechanism of Action for C-15/C-20 Analogs. *ACS omega* **2022**, *7* (10), 8824-8832.